• Rokas Serpytis, Egle Majauskiene, Petras Navickas, Mindaugas Lizaitis, Sigita Glaveckaite, Kestutis Rucinskas, Zaneta Petrulioniene, Nomeda Valeviciene, Robertas Stasys Samalavicius, Andrius Berukstis, Arvydas Baranauskas, Urte Gargalskaite, Aleksandras Laucevicius, Qin M Chen, Joseph S Alpert, and Pranas Serpytis.
• Clinic of Heart and Vessel Diseases, Institute of Clinical Medicine Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
• Am. J. Med. 2022 Jan 1; 135 (1): 103-109.

BackgroundMyocardial infarction with nonobstructive coronary arteries (MINOCA) remains an unresolved challenge. Many different diagnostic approaches are often required to diagnose, confirm, and evaluate MINOCA. The prevalence can be as high as 13% of all acute myocardial infarction patients, indicating that this condition is not rare. At this time, there have been no completed randomized clinical trials involving MINOCA patients, and a better understanding of the mechanisms and management of these patients is important. This exploratory analysis seeks to find possible etiologic factors, the value of novel biomarkers, and the effect of different treatment strategies in patients with MINOCA.MethodsThis prospective randomized pilot trial will include 150 patients with MINOCA. A thorough clinical, laboratory, and imaging evaluation will be performed, including novel biomarkers and modern imaging techniques (heart magnetic resonance imaging and noninvasive testing). The duration of the enrollment is 18 months, and duration of the follow-up is 12 months from the enrollment of the first patient.ResultsThe trial is registered under www.clinicaltrials.gov: NCT04538924. The study is currently recruiting participants.ConclusionsBecause MINOCA is not a benign disease, the results of the current investigation could inform future diagnostic and therapeutic strategies and enhance the understanding of MINOCA patients.Copyright © 2021. Published by Elsevier Inc.

10 keywords...

hide…